

CURRICULUM VITAE

PERSONAL DATA

Name NAVARINI-MEURY Alexander Andreas
Academic title Prof. M.D. Ph.D. / Prof. Dr. med. Dr. sc.nat.
Date and 14 February 1976
Place of Birth Basel, Switzerland
Nationality Swiss
Marital status and children married, 2 children

Position and Professional Address Oberarzt / Attending physician
Dermatologische Klinik, USZ, Zürich
Gloriastrasse 31, 8091 Zürich
Tel +41 44 255 16 38
Fax +41 44 255 44 03
Private Address Therwilerstrasse 74a, 4153 Reinach,
+41 76 423 14 00
E-Mail alexander.navarini@usz.ch



EDUCATION

11/2010, 08/2010 **Swiss (FMH) and European Board Examination for Specialization in Dermatology and Venereology**
2008, 2011, 2014 **Good Clinical Practice Certificates 1,2,3 (Principal investigator for clinical trials)**
2003, 2005, 2010 **Animal research permits 1,2,3E (Principal investigator for animal experiments)**
06/2007 **Ph.D. (Dissertation).** University of Zurich.
03/2003 - 06/2006 **Postgraduate Course in Experimental Medicine and Biology and MD PhD Studies.** Institute of Experimental Immunology, University of Zurich, Switzerland, Prof. R.M. Zinkernagel and Prof. H. Hengartner, PhD co-directed by Prof. A. Aguzzi
01/2004 **Medical Doctoral Degree (Dissertation).** University of Zurich
2003 **United States Medical Licencing Examination 1 and 2**
11/2002 **Swiss National Board Examination for Medicine.** University of Basel, Switzerland.
1996-2002 **Medical School** at University of Basel and Université Marie-Curie, Paris, France.

PROFESSIONAL APPOINTMENTS AND ACTIVITIES

01/2016 – present **Deputy Head of outpatient clinic, Department of Dermatology, USZ**
08/2015 – present **Professor of Immunodermatology, head of patch testing laboratory, psoriasis & acne clinic**
05/2014 – present **Attending physician (Oberarzt), head of psoriasis & acne clinic**
05/2012 – 04/2014 **Senior Visiting Research Fellow** at Division of Genetics and Molecular Medicine, St John's Institute of Dermatology, King's College, London, United Kingdom
05/2012 **Senior Lecturer (Privatdozent),** University of Zurich

11/2007 - 05/2012	Lecturing and Tutoring , Department of Dermatology, University Hospital of Zurich
01/2011 - 05/2012	Attending physician (Oberarzt i.V.) head of psoriasis clinic , Department of Dermatology, University Hospital of Zurich
11/2007 - 05/2012	Principal Investigator , Department of Dermatology, University Hospital of Zurich
11/2007 - 11/2010	Resident , Dermatology, Department of Dermatology, University Hospital of Zurich, Prof. Lars E. French
01/2007 - 09/2007	Resident , Tropical Medicine and Infectiology, St Francis Hospital, Tanzania, Swiss Tropical Institute, Prof. Ch. Hatz
07/2006 - 12/2006	Resident , Internal Medicine, Bruderholzspital, Basel, Prof. R. Krapf

ACADEMIC LEADERSHIP

2007 - present	1 postdoctoral fellow, 9 current/past MD or PhD students, 8 current/past MSc
2011 - present	Founder of specialist group "clinical skills and translational dermatology" with annual workshop at national congress of Dermatology.
05/2012 - 03/2014	Physician of task force <i>Personalized Medicine of the TA Swiss Institute</i>.

INVESTIGATOR-INITIATED TRIALS

NCT01952275	Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases (recruiting since January 2014)
NCT01302795	Phase II multicenter open-label pilot study to assess a potential effect of an IL-1- β antagonist in the treatment of pyoderma gangrenosum (completed)
NCT01635127	Phase II singlecenter double-blind placebo-controlled efficacy Study of Canakinumab to Treat Urticaria (URTICANA) (ongoing, recruiting since July 2012)
NCT01254240	Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases (PRUVAB) (completed and published)
NCT01044043	Prevalence and subjective impairment of quality of life (QoL) due to dermatologic diseases in internal medicine patients (completed and published)

AWARDS, HONOURS

2016	Mentor for Future Leaders of the European Society of Dermatological Research, Madrid
2015	Bruno Bloch – Promedica Professorship for Immunodermatology
2015	European Society of Dermatological Research Acne & Rosacea Award
2015	Entrepreneur in Clinical Academia Participant, INSEAD, Fontainebleau
2011	Future Leader, European Society of Dermatological Research, Cascais

RESEARCH GRANTS AND EXTERNAL FUNDING (LAST 5 YEARS, 2.10 MIO CHF)

LONGTERM PROJECTS AIMING TO BUILD RESOURCES

2010 - ongoing	Lead of the Biobank for Inflammatory Dermatoses, Department of Dermatology, University Hospital of Zurich. KEK-ZH-NR: 2010-0117/0
2012 - ongoing	Principal Investigator of the European Rare and Severe Psoriasis Network (ERASPEN) for harmonizing phenotype descriptions (funded by EADV for 2013-2016)

PUBLICATIONS

Total peer-reviewed publications:	83
h index (Google Scholar):	22, since 2011: 20
i10 index (Google Scholar):	44, since 2011: 42
Sum of times cited :	2112
Average citations per item (ISI):	16.37
First, shared first and last authorships:	20 original works, 23 cases/reviews

PUBLICATION LIST OF LAST 1 YEAR

Peer-reviewed articles:

1. **Navarini AA***, Hruz P*, Berger CT*, Hou TZ*, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg Sgier PC, Käme O, Burgener AV, Marquardsen F, Baldin F, Bigler M, Kistner A, Jauch A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker LT, Heijnen I, Daikeler TD, Gebbers JO, Grimbacher B, Sansom DM, Jeker R, Hess C, Recher M. Vedolizumab as a successful treatment of CTLA-4 associated autoimmune enterocolitis. **J Allergy Clin Immunol.** 2016 (accepted). (* = shared first author)
Impact factor 12.037
2. Kolios AG, Yawalkar N, Anliker M, Boehncke WH, Borradori L, Conrad C, Gilliet M, Häusermann P, Itin P, Laffitte E, Mainetti C, French LE, **Navarini AA.** Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. *Dermatology.* 2016 Jun 21. [Epub ahead of print]
Impact factor 2.741
3. Anzengruber F, Maul JT, Kamarachev J, Trüeb RM, French LE, **Navarini AA.** Transient Efficacy of Tofacitinib in Alopecia Areata Universalis. *Case Rep Dermatol.* 2016 Apr 22;8(1):102-6. doi: 10.1159/000445182. eCollection 2016 Jan-Apr.
4. Di Meglio P*, Villanova F*, **Navarini AA***, Mylonas A, Tosi I, Nestle FO, Conrad C. Targeting CD8+ T cells prevents psoriasis development. **J Allergy Clin Immunol.** 2016 Jan 9. pii: S0091-6749(15)01735-2. doi: 10.1016/j.jaci.2015.10.046 (* = shared first author)
Impact factor 12.037
5. Guenova E, Ignatova D, Chang YT, Contassot E, Mehra T, Saulite I, **Navarini AA,** Mitev V, Dummer R, Kazakov DV, French LE, Hötzenecker W, Cozzio A. Expression of CD164 on Malignant T Cells in Sézary Syndrome. **Acta Derm Venereol.** 2015 Nov 2. doi: 10.2340/00015555-2264. [Epub ahead of print]
Impact factor 3.72
6. Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, Zillikens D, Röcken M, Ring J, Facchiano A, Mondino C, Yawalkar N, Contassot E, **Navarini AA,** French LE. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. *Br J Dermatol.* 2015 Oct 16. doi: 10.1111/bjd.14037. [Epub ahead of print]
Impact factor 4.275
7. Maul JT, Carraro S, Stierlin J, Geiges ML, Navarini AA. Beauty and the Biologic: Artistic Documentation of Scientific Breakthrough in Psoriasis. **Case Rep Dermatol.** 2015 Sep 25;7(3):249-52. doi: 10.1159/000439583. eCollection 2015 Sep-Dec
8. Merches K, Khairnar V, Knuschke T, Shaabani N, Honke N, Duhan V, Recher M, **Navarini AA,** Hardt C, Häussinger D, Tümmler B, Gulbins E, Futerman AH, Hoffmann D, Lang F, Lang PA, Westendorf AM, Lang KS. Virus-Induced Type I Interferon Deteriorates Control of Systemic Pseudomonas Aeruginosa Infection. **Cell Physiol Biochem.** 2015;36(6):2379-92
Impact factor 2.875
9. Berki DM, Liu L, Choon SE, David Burden A, Griffiths CE, **Navarini AA,** Tan ES, Irvine AD, Ranki A, Ogo T, Petrof G, Mahil SK, Duckworth M, Allen MH, Vito P, Trembath RC, McGrath J, Smith CH, Capon F, Barker JN. Activating CARD14 Mutations Are Associated With Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. **J Invest Dermatol.** 2015 Jul 23.
Impact factor 7.216
10. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, **Navarini A,** Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. **Inflamm Bowel Dis.** 2015 Aug;21(8):1982-92
Impact factor 4.464
11. Kolev M, Dimeloe S, Le Fric G, **Navarini A,** Arbore G, Povoleri GA, Fischer M, Belle R, Loeliger J, Develioglu L, Bantug GR, Watson J, Couzi L, Afzali B, Lavender P, Hess C, Kemper C. Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses. **Immunity.** 2015 Jun 16;42(6):1033-47.
Impact factor 21.561
12. Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, **Navarini AA,** French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory

Bowel Disease Cohort. **Inflamm Bowel Dis.** 2015 Aug;21(8):1794-80
Impact factor 4.464

13. Kolios AGA, French LE, **Navarini AA**. Detection of small changes in psoriasis intensity with the PrecisePASI. **Dermatology** 2015 Mar 10. [Epub ahead of print]
Impact factor 2.741
14. Imhof L, Meier B, Frei P, Kamarachev J, Rogler G, Kolios A, **Navarini AA**, Contassot E, French LE. Severe Sweet's syndrome with elevated cutaneous interleukin 1 beta after azathioprine exposure. Case report and review of the literature. **Dermatology** 2015 Mar 14. [Epub ahead of print],
Impact factor 2.741
15. Boehncke WH, Anliker MD, Conrad C, Dudler J, Hasler F, Hasler P, Häusermann P, Kyburz D, Laffitte E, Michel BA, Möller B, **Navarini AA**, Villiger PM, Yawalkar N, Gabay C. The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists. **Dermatology.** 2015 Jan 6. [Epub ahead of print]
Impact factor 2.741
16. Tackenberg S, Gehrig A, Dummer R, **Navarini AA** (2011). *Radiotherapy of extramammary paget's disease.* **Cutis** Cutis. 2015 Feb;95(2):109-12.
Impact factor 1.019

Reviews:

1. **Navarini AA**, French LE. The skin and its blossoms--fertile soil for clinical science. **Semin Immunopathol.** 2016 Jan;38(1):1-2. doi: 10.1007/s00281-015-0546-9. Epub 2015 Nov 24.
Impact factor 6.4
2. **Navarini AA**, Satoh T, French LE. Neutrophilic dermatoses and autoinflammatory diseases with skin involvement as innate immune disorders. **Semin Immunopathol.** 2015 Sep 30.
Impact factor 6.4
3. Schlapbach C, **Navarini AA** The continuing evolution of targeted therapy for inflammatory skin disease. **Semin Immunopathol.** 2015 Sep 30.
Impact factor 6.4

Book contributions

1. **Navarini AA**, Borradori L, Saurat JH. Les pustuloses amicrobiennes. **Dermatologie et Venerologie**, 6ème edition 2016, Flammarion
2. **Navarini AA**. Psoriasis. **ESC Textbook of Cardiology**, Oxford University Press, Editors: T. Lüscher et al. 3rd Edition (in press)

Signed, Date